When transmission benefits were included in the analysis, initiating treatment with HAART at a CD4 count of either 350 or 500 cells/μL (Tables 6 and 7) was cost-saving for both the ED-inpatient and STD-ED comparisons (except at the upper bound of the 95% confidence interval). Here, CD4 is linked to sexually transmitted disease.